JP4498274B2 - 二量体化ペプチド - Google Patents

二量体化ペプチド Download PDF

Info

Publication number: JP4498274B2
Authority: JP; Japan
Prior art keywords: peptide; cancer; residue; dimer; ctl
Prior art date: 2003-01-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2005508011A

Other languages

English (en)

Japanese (ja)

Other versions

JPWO2004063217A1 (ja

Inventor

治夫杉山

秀夫高須

文雄三溝

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chugai Pharmaceutical Co Ltd

International Institute of Cancer Immunology Inc

Sumitomo Pharma Co Ltd

Original Assignee

Chugai Pharmaceutical Co Ltd

Sumitomo Dainippon Pharma Co Ltd

International Institute of Cancer Immunology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-15

Filing date

2004-01-15

Publication date

2010-07-07

2004-01-15 Application filed by Chugai Pharmaceutical Co Ltd, Sumitomo Dainippon Pharma Co Ltd, International Institute of Cancer Immunology Inc filed Critical Chugai Pharmaceutical Co Ltd

2006-06-01 Publication of JPWO2004063217A1 publication Critical patent/JPWO2004063217A1/ja

2010-07-07 Application granted granted Critical

2010-07-07 Publication of JP4498274B2 publication Critical patent/JP4498274B2/ja

2024-01-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 126
239000000539 dimer Substances 0.000 claims abstract description 39
YNOVBMBQSQTLFM-DCAQKATOSA-N Met-Asn-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O YNOVBMBQSQTLFM-DCAQKATOSA-N 0.000 claims description 3
NAQBQJOGGYGCOT-QEJZJMRPSA-N Trp-Asn-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O NAQBQJOGGYGCOT-QEJZJMRPSA-N 0.000 claims description 3
VXDXZGYXHIADHF-YJRXYDGGSA-N Cys-Tyr-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VXDXZGYXHIADHF-YJRXYDGGSA-N 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 abstract description 55
108091007433 antigens Proteins 0.000 abstract description 34
102000036639 antigens Human genes 0.000 abstract description 34
239000000178 monomer Substances 0.000 abstract description 31
239000000427 antigen Substances 0.000 abstract description 27
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract description 16
150000001413 amino acids Chemical class 0.000 abstract description 14
235000001014 amino acid Nutrition 0.000 abstract description 11
229940022399 cancer vaccine Drugs 0.000 abstract description 8
238000009566 cancer vaccine Methods 0.000 abstract description 8
201000011510 cancer Diseases 0.000 description 50
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 29
210000004027 cell Anatomy 0.000 description 25
238000000034 method Methods 0.000 description 16
239000000243 solution Substances 0.000 description 15
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 14
230000001939 inductive effect Effects 0.000 description 13
239000011347 resin Substances 0.000 description 13
229920005989 resin Polymers 0.000 description 13
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 12
239000008194 pharmaceutical composition Substances 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 12
238000010647 peptide synthesis reaction Methods 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
101150084041 WT1 gene Proteins 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
108700020467 WT1 Proteins 0.000 description 8
102000040856 WT1 Human genes 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
239000007788 liquid Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
108010013476 HLA-A24 Antigen Proteins 0.000 description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
125000006178 methyl benzyl group Chemical group 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000007800 oxidant agent Substances 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
-1 potassium ferricyanide Chemical compound 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 2
LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 2
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 2
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
BJJRNAVDQGREGC-HOUAVDHOSA-N Thr-Trp-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O BJJRNAVDQGREGC-HOUAVDHOSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
201000003115 germ cell cancer Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002998 immunogenetic effect Effects 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000012264 purified product Substances 0.000 description 2
201000000849 skin cancer Diseases 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
238000003756 stirring Methods 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
239000004474 valine Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
ZXKNLCPUNZPFGY-LEWSCRJBSA-N Ala-Tyr-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N ZXKNLCPUNZPFGY-LEWSCRJBSA-N 0.000 description 1
PYDIIVKGTBRIEL-SZMVWBNQSA-N Arg-Trp-Pro Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(O)=O PYDIIVKGTBRIEL-SZMVWBNQSA-N 0.000 description 1
NUHQMYUWLUSRJX-BIIVOSGPSA-N Asn-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N NUHQMYUWLUSRJX-BIIVOSGPSA-N 0.000 description 1
UWOPETAWXDZUJR-ACZMJKKPSA-N Asp-Cys-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O UWOPETAWXDZUJR-ACZMJKKPSA-N 0.000 description 1
JUWISGAGWSDGDH-KKUMJFAQSA-N Asp-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=CC=C1 JUWISGAGWSDGDH-KKUMJFAQSA-N 0.000 description 1
FIAKNCXQFFKSSI-ZLUOBGJFSA-N Asp-Ser-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O FIAKNCXQFFKSSI-ZLUOBGJFSA-N 0.000 description 1
SNHRIJBANHPWMO-XGEHTFHBSA-N Cys-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N)O SNHRIJBANHPWMO-XGEHTFHBSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010012559 Developmental delay Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
YDWZGVCXMVLDQH-WHFBIAKZSA-N Gly-Cys-Asn Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(N)=O YDWZGVCXMVLDQH-WHFBIAKZSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
GGAPIOORBXHMNY-ULQDDVLXSA-N Lys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)O GGAPIOORBXHMNY-ULQDDVLXSA-N 0.000 description 1
ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
102000003425 Tyrosinase Human genes 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
208000006038 Urogenital Abnormalities Diseases 0.000 description 1
201000007960 WAGR syndrome Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
102000046004 human WT1 Human genes 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
239000002502 liposome Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
239000000463 material Substances 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000002994 raw material Substances 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000012546 transfer Methods 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

JP2005508011A 2003-01-15 2004-01-15 二量体化ペプチド Expired - Lifetime JP4498274B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2003007122		2003-01-15
JP2003007122		2003-01-15
PCT/JP2004/000254 WO2004063217A1 (fr)	2003-01-15	2004-01-15	Peptide dimerise

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009260957A Division JP4926231B2 (ja)	2003-01-15	2009-11-16	二量体化ペプチド

Publications (2)

Publication Number	Publication Date
JPWO2004063217A1 JPWO2004063217A1 (ja)	2006-06-01
JP4498274B2 true JP4498274B2 (ja)	2010-07-07

Family

ID=32709100

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2005508011A Expired - Lifetime JP4498274B2 (ja)	2003-01-15	2004-01-15	二量体化ペプチド
JP2009260957A Expired - Lifetime JP4926231B2 (ja)	2003-01-15	2009-11-16	二量体化ペプチド

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009260957A Expired - Lifetime JP4926231B2 (ja)	2003-01-15	2009-11-16	二量体化ペプチド

Country Status (13)

Country	Link
US (2)	US20060217297A1 (fr)
EP (2)	EP2154145B1 (fr)
JP (2)	JP4498274B2 (fr)
KR (2)	KR20120054644A (fr)
CN (2)	CN1756763B (fr)
AT (1)	ATE444969T1 (fr)
AU (1)	AU2004204031B2 (fr)
BR (1)	BRPI0406800B8 (fr)
CA (1)	CA2513701C (fr)
DE (1)	DE602004023476D1 (fr)
ES (1)	ES2332590T3 (fr)
HK (2)	HK1081975A1 (fr)
WO (1)	WO2004063217A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1560078B (zh) *	1998-07-31	2011-06-22	株式会社国际癌症免疫研究所	基于癌抑制基因wt1的产物的癌抗原
CA2440303C (fr) *	2001-03-22	2013-03-19	Haruo Sugiyama	Peptide modifie wt1
WO2002097044A2 (fr) *	2001-05-25	2002-12-05	Thomas Jefferson University	Formes d'epissage alternatives de proteines servant de base pour modalites therapeutiques multiples
ES2538486T3 (es) *	2002-09-12	2015-06-22	International Institute Of Cancer Immunology, Inc.	Preparación de péptidos antigénicos contra el cáncer
KR101213015B1 (ko)	2003-11-05	2012-12-26	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
SI1731605T1 (sl) *	2004-03-31	2010-07-30	Internat Inst Of Cancer Immunolog Inc	Peptidi antigena karcinoma izvedeni iz WT1
RU2396088C2 (ru) *	2005-02-04	2010-08-10	СУРВАК АпС	Вакцина на основе пептидов сурвивина
CN101336249A (zh)	2005-11-30	2008-12-31	株式会社癌免疫研究所	新型肽化合物
PL1988163T3 (pl)	2006-02-22	2012-11-30	Int Inst Cancer Immunology Inc	Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
ATE443722T1 (de) *	2006-02-23	2009-10-15	Fibrex Medical Res & Dev Gmbh	Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
CA2886619A1 (fr)	2006-12-28	2008-07-10	International Institute Of Cancer Immunology, Inc.	Peptide wt1 a restriction hla-a<sp>*</sp>1101 et composition pharmaceutique le contenant
CN104774910B (zh)	2007-02-27	2018-04-10	株式会社癌免疫研究所	活化辅助t细胞的方法以及用于该方法的组合物
AU2008292913B2 (en) *	2007-08-30	2014-06-05	Curedm Group Holdings, Llc	Compositions and methods of using proislet peptides and analogs thereof
ES2849187T3 (es)	2010-10-05	2021-08-16	Int Inst Cancer Immunology Inc	Método para activar células T auxiliares
NZ611176A (en)	2010-12-02	2015-07-31	Bionor Immuno As	Peptide scaffold design
JP5893640B2 (ja) *	2010-12-23	2016-03-23	ファルネファオーストリアゲーエムベーハー	Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用
MX346475B (es)	2011-01-06	2017-03-22	Bionor Immuno As	Peptidos inmunogenicos monomericos y multimericos.
WO2012105224A1 (fr) *	2011-01-31	2012-08-09	オリンパス株式会社	Adjuvant de vaccin
ES2655031T3 (es)	2012-07-02	2018-02-16	Sumitomo Dainippon Pharma Co., Ltd.	Preparación transdérmica de péptido antigénico del cáncer
JP6530192B2 (ja)	2012-12-17	2019-06-12	大塚製薬株式会社	ヘルパーｔ細胞の活性化方法
JP6294868B2 (ja)	2013-03-12	2018-03-14	大日本住友製薬株式会社	液体水性組成物
DK2982681T3 (en) *	2013-03-29	2018-12-10	Sumitomo Dainippon Pharma Co Ltd	WT1 ANTIGENPEPTIDKONJUGATVACCINE
JP6671956B2 (ja) *	2013-03-29	2020-03-25	大日本住友製薬株式会社	Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
EP3059242A4 (fr)	2013-10-17	2017-04-19	Seoul National University R&DB Foundation	Multimère de peptides de pénétration cellulaire à hélice alpha, procédé de préparation associé et utilisation associée
US10471136B2 (en)	2014-09-27	2019-11-12	Sumitomo Dainippon Pharma Co., Ltd.	Pharmaceutical composition for injection
JP6671141B2 (ja) *	2014-10-21	2020-03-25	大日本住友製薬株式会社	懸濁液剤
CN107921106B (zh) *	2015-05-20	2023-09-08	住友制药株式会社	Wt1抗原肽和免疫调节剂的组合用途
EP3322989A1 (fr)	2015-07-14	2018-05-23	Yeda Research and Development Co., Ltd.	Combinaisons de peptides à utiliser pour le diagnostic de la schizophrénie
US20200368338A1 (en) *	2017-12-27	2020-11-26	Sumitomo Dainippon Pharma Co., Ltd.	Conjugate of wt1-derived peptides and composition comprising the same
US20240207426A1 (en) *	2022-12-22	2024-06-27	Defence Therapeutics Inc.	Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002525099A (ja) *	1998-09-30	2002-08-13	コリクサコーポレイション	Ｗｔ１特異的免疫療法のための組成物および方法
WO2002079253A1 (fr) *	2001-03-22	2002-10-10	Haruo Sugiyama	Peptide modifie wt1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0841068B1 (fr) *	1995-06-01	2006-07-12	Kishimoto, Tadamitsu	Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1)
JP3060287B2 (ja)	1995-10-09	2000-07-10	参天製薬株式会社	アパファントを主薬とする水性点眼剤
CN1560078B (zh) *	1998-07-31	2011-06-22	株式会社国际癌症免疫研究所	基于癌抑制基因wt1的产物的癌抗原
US7063854B1 (en) *	1998-09-30	2006-06-20	Corixa Corporation	Composition and methods for WTI specific immunotherapy
GB9823897D0 (en) *	1998-11-02	1998-12-30	Imp College Innovations Ltd	Immunotherapeutic methods and molecules
WO2002047474A1 (fr)	2000-12-13	2002-06-20	Sumitomo Pharmaceuticals Company, Limited	Animaux transgeniques exprimant hla-a24 et utilisation de ceux-ci
US8735357B2 (en) *	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
JPWO2003028758A1 (ja) *	2001-09-28	2005-01-13	治夫杉山	抗原特異的ｔ細胞の誘導方法
ATE466084T1 (de) *	2002-06-12	2010-05-15	Int Inst Cancer Immunology Inc	Hla-a24-restringiertes krebsantigenpeptid
KR101213015B1 (ko)	2003-11-05	2012-12-26	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
SI1731605T1 (sl)	2004-03-31	2010-07-30	Internat Inst Of Cancer Immunolog Inc	Peptidi antigena karcinoma izvedeni iz WT1

2004
- 2004-01-15 US US10/541,821 patent/US20060217297A1/en not_active Abandoned
- 2004-01-15 CA CA2513701A patent/CA2513701C/fr not_active Expired - Lifetime
- 2004-01-15 KR KR1020127008760A patent/KR20120054644A/ko not_active Application Discontinuation
- 2004-01-15 EP EP09172205.8A patent/EP2154145B1/fr not_active Expired - Lifetime
- 2004-01-15 AT AT04702444T patent/ATE444969T1/de not_active IP Right Cessation
- 2004-01-15 EP EP04702444A patent/EP1584627B1/fr not_active Expired - Lifetime
- 2004-01-15 ES ES04702444T patent/ES2332590T3/es not_active Expired - Lifetime
- 2004-01-15 DE DE602004023476T patent/DE602004023476D1/de not_active Expired - Lifetime
- 2004-01-15 CN CN2004800058473A patent/CN1756763B/zh not_active Expired - Lifetime
- 2004-01-15 KR KR1020057012761A patent/KR101399678B1/ko active IP Right Grant
- 2004-01-15 CN CN201010156098A patent/CN101851275A/zh active Pending
- 2004-01-15 JP JP2005508011A patent/JP4498274B2/ja not_active Expired - Lifetime
- 2004-01-15 BR BRPI0406800A patent/BRPI0406800B8/pt active IP Right Grant
- 2004-01-15 WO PCT/JP2004/000254 patent/WO2004063217A1/fr active Application Filing
- 2004-01-15 AU AU2004204031A patent/AU2004204031B2/en not_active Expired
2006
- 2006-02-23 HK HK06102442.4A patent/HK1081975A1/xx not_active IP Right Cessation
2009
- 2009-11-16 JP JP2009260957A patent/JP4926231B2/ja not_active Expired - Lifetime
2010
- 2010-06-07 US US12/795,187 patent/US8242084B2/en not_active Expired - Lifetime
- 2010-08-16 HK HK10107803.0A patent/HK1141539A1/xx not_active IP Right Cessation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002525099A (ja) *	1998-09-30	2002-08-13	コリクサコーポレイション	Ｗｔ１特異的免疫療法のための組成物および方法
WO2002079253A1 (fr) *	2001-03-22	2002-10-10	Haruo Sugiyama	Peptide modifie wt1

Also Published As

Publication number	Publication date
US20060217297A1 (en)	2006-09-28
JP4926231B2 (ja)	2012-05-09
EP1584627A4 (fr)	2006-03-15
CN101851275A (zh)	2010-10-06
AU2004204031B2 (en)	2010-03-04
KR20120054644A (ko)	2012-05-30
JPWO2004063217A1 (ja)	2006-06-01
KR101399678B1 (ko)	2014-05-27
HK1141539A1 (en)	2010-11-12
BRPI0406800B8 (pt)	2021-05-25
ES2332590T3 (es)	2010-02-09
CN1756763B (zh)	2010-05-26
US20100292164A1 (en)	2010-11-18
JP2010047603A (ja)	2010-03-04
HK1081975A1 (en)	2006-05-26
DE602004023476D1 (de)	2009-11-19
WO2004063217A1 (fr)	2004-07-29
EP2154145A3 (fr)	2010-05-19
CA2513701C (fr)	2013-06-18
EP2154145A2 (fr)	2010-02-17
CN1756763A (zh)	2006-04-05
BRPI0406800A8 (pt)	2016-11-01
US8242084B2 (en)	2012-08-14
AU2004204031A1 (en)	2004-07-29
BRPI0406800A (pt)	2006-01-17
KR20050098863A (ko)	2005-10-12
ATE444969T1 (de)	2009-10-15
CA2513701A1 (fr)	2004-07-29
EP1584627A1 (fr)	2005-10-12
BRPI0406800B1 (pt)	2020-08-11
EP2154145B1 (fr)	2013-04-24
EP1584627B1 (fr)	2009-10-07

Legal Events

Date	Code	Title	Description
2006-03-04	A711	Notification of change in applicant	Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060303
2006-12-19	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061218
2009-09-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090915
2009-11-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091116
2010-01-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105
2010-03-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100305
2010-03-25	TRDD	Decision of grant or rejection written
2010-03-31	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100330
2010-04-01	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2010-04-22	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100413
2010-04-23	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3
2010-04-23	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4498274 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2013-03-12	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20140423 Year of fee payment: 4
2013-03-12	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-03-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-04-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-04-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-06-06	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313117
2016-06-14	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2017-03-14	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-02-27	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-02-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-02-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-03-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-02-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-04-28	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2022-04-28	S533	Written request for registration of change of name	Free format text: JAPANESE INTERMEDIATE CODE: R313533
2022-05-17	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2023-02-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-01-15	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JP4926231B2 (ja)	2012-05-09	二量体化ペプチド
JP7248247B2 (ja)	2023-03-29	Ｗｔ１抗原ペプチドコンジュゲートワクチン
JP5800928B2 (ja)	2015-10-28	新規ペプチド化合物
WO2014157704A1 (fr)	2014-10-02	Vaccin conjugué utilisant une fonction de rognage de erap1
HUE026977T2 (en)	2016-08-29	Promiseness HER-2 / NEU CD4 T-cell epitopes